Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>(A-D) YUO-006 and YUO-010 (Patient-derived organoids), YU-1089 and YU-1095 (Patient-derived cells) or HCC827-AR and H820 (ATCC cell lines) were seeded on a 96-well plate and incubated with the MET TKIs (tepotinib) and EGFR TKIs (osimertinib or gefitinib) for 3 days. EGFR TKIs was treated wi...

全面介紹

Saved in:
書目詳細資料
主要作者: Seung Yeon Oh (15051017) (author)
其他作者: You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
出版: 2025
主題:
Cancer
Therapeutic Research and Development
Drug Resistance
Clinical drug resistance
Lung Cancer
Translational Research
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍